Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company’s recently approved fibromyalgia treatment. TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%.
The strong performance of TONMYA underscores its rapid adoption in the market. The drug currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This broadening access is likely to further boost sales and solidify TONMYA’s position as a leading treatment for fibromyalgia, a condition that has seen limited therapeutic options.
Beyond commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These initiatives highlight Tonix’s commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides a solid foundation for continued investment in its commercial and clinical programs.
The robust revenue growth and pipeline progress are critical for Tonix as it seeks to establish itself as a fully-integrated, commercial-stage biotechnology company. The company’s focus on CNS and immunology treatments in areas of high unmet medical need positions it to capture significant market opportunities. With TONMYA’s strong sales trajectory and the potential of its pipeline candidates, Tonix is well-positioned for sustained growth.
Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease.
In the immunology space, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs reflect the company’s broad research and development efforts aimed at delivering innovative therapies.
The positive momentum in Tonix’s commercial and clinical activities is a testament to its strategic execution. As TONMYA continues to gain market share and the pipeline advances, Tonix is poised to make a lasting impact on patients’ lives and create value for shareholders. For more information on the full press release, visit https://nnw.fm/6Yytj.
